Home Newsfeeds Baird Upgrades Biogen to Outperform, Raises Price Target to $340

Baird Upgrades Biogen to Outperform, Raises Price Target to $340

Baird analyst Brian Skorney upgrades Biogen (NASDAQ:BIIB) from Neutral to Outperform and raises the price target from $224 to $340.

byBenzinga Newsdesk

September 28, 2022

1 minute read

Baird analyst Brian Skorney upgrades Biogen (NASDAQ:BIIB) from Neutral to Outperform and raises the price target from $224 to $340.

Elon Musk Said To Be In Talks With India’s Richest Man To Help Take Tesla To India

By Shomik Sen Bhattacharjee

April 10, 4:00 AM

This story was first published on the Benzinga India portal.

TSLA

P/E Ratio Insights for ING Groep

By Benzinga Insights

September 28, 1:30 PM

In the current market session, ING Groep Inc. (NYSE:ING) share price is at $13.26, after a 1.88% spike.…

ING

Susquehanna Maintains Neutral on TransDigm Gr, Raises Price Target to $750

By Benzinga Newsdesk

February 8, 10:12 AM

Susquehanna analyst Charles Minervino maintains TransDigm Gr (NYSE:TDG) with a Neutral and raises the price target from $665 to $750.

TDG

Elizabeth Warren Questions CFTC Chair On Frequent Interactions With Jailed FTX Founder Sam Bankman-Fried: Provide ‘Full Accounting Of All Conversations’

By Benzinga Neuro

April 16, 2:43 AM

Senator Warren and Grassley have issued a letter to Behnam asking for a comprehensive record of his interactions with Bankman-Fried during his tenure. This request comes in the wake of disclosures that CFTC officials had met with Bankman-Fried and his team as many as 10 times at the agency over a span of 14 months.